rs375661583
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PP3_ModerateBS2
The NM_000169.3(GLA):c.1184G>C(p.Gly395Ala) variant causes a missense change. The variant allele was found at a frequency of 0.0000132 in 1,208,708 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 3 hemizygotes in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000169.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000355 AC: 4AN: 112547Hom.: 0 Cov.: 23 AF XY: 0.0000288 AC XY: 1AN XY: 34743
GnomAD3 exomes AF: 0.0000109 AC: 2AN: 183463Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 67899
GnomAD4 exome AF: 0.0000109 AC: 12AN: 1096161Hom.: 0 Cov.: 30 AF XY: 0.00000553 AC XY: 2AN XY: 361545
GnomAD4 genome AF: 0.0000355 AC: 4AN: 112547Hom.: 0 Cov.: 23 AF XY: 0.0000288 AC XY: 1AN XY: 34743
ClinVar
Submissions by phenotype
Fabry disease Uncertain:5
This missense variant replaces glycine with alanine at codon 395 of the GLA protein. Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant leads to a 13-24% level of residual GLA enzyme activity when expressed in HEK293 cells (PMID: 21598360). This variant has been reported in a few individuals and families affected with Fabry disease (PMID: 26880903, 27825144, 29487688, 30477121, 35971858, 36709535), in an individual suspected of having Fabry disease (PMID: 21896204), and in five asymptomatic relatives of the affected carriers (PMID: 29487688, 32806660). This variant has been identified in 2/183463 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.Gly395Ala variant in GLA has been reported in up to 10 Southern Italian families with Fabry disease (PMID: 21896204, 29487688, 27825144), and has been identified in 0.0024% (2/81904) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs375661583). Although this variant has been seen in the general population, its frequency is low enough to be consistent with Fabry Disease. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. The number of reported affected individuals with this variant is slightly greater than expected compared to non-affected individuals with this variant. This variant has also been reported in ClinVar as a VUS by Invitae (ID: 405511). In vitro functional studies provide some evidence that the p.Gly395Ala variant may slightly impact protein function through decreased enzyme function (PMID: 23935525). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The phenotype of an individual hemizygous for this variant is highly specific for Fabry disease based on the classic phenotype that is consistent with disease (PMID: 21896204, 29487688, 27825144). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PP4, PM2_supporting, PP3, PS4_supporting, PS3_supporting (Richards 2015). -
This sequence change replaces glycine with alanine at codon 395 of the GLA protein (p.Gly395Ala). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and alanine. This variant is present in population databases (rs375661583, ExAC 0.002%). This missense change has been observed in individual(s) with clinical features of Fabry disease (PMID: 21896204, 27825144, 29487688, 30477121). ClinVar contains an entry for this variant (Variation ID: 405511). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Experimental studies have shown that this missense change affects GLA function (PMID: 23935525). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
This missense variant replaces glycine with alanine at codon 395 of the GLA protein. Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant leads to a 13-24% level of residual GLA enzyme activity when expressed in HEK293 cells (PMID: 21598360). This variant has been reported in a few individuals and families affected with Fabry disease (PMID: 26880903, 27825144, 29487688, 30477121, 35971858, 36709535), in an individual suspected of having Fabry disease (PMID: 21896204), and in five asymptomatic relatives of the affected carriers (PMID: 29487688, 32806660). This variant has been identified in 2/183463 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
- -
not provided Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at